Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients"

Kardiol Pol. 2016;74(5):506. doi: 10.5603/KP.2016.0073.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation
  • Factor Xa Inhibitors / therapeutic use
  • Follow-Up Studies
  • Humans
  • Morpholines / therapeutic use
  • Rivaroxaban*
  • Secondary Prevention
  • Stroke*
  • Thiophenes / therapeutic use
  • Treatment Outcome
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Morpholines
  • Thiophenes
  • Warfarin
  • Rivaroxaban